De COGEM heeft een nieuwe signalering gepubliceerd, waarin zij verkent hoeveel nieuwe gentherapieën in de pijplijn zitten, wat de kosten zijn, en de dilemma’s en keuzes die met de komst van deze therapieën gepaard gaan. Ook wordt ingegaan op de instrumenten die de overheid heeft om gentherapieën betaalbaar en beschikbaar te houden.
Lees het document hier.
The Netherlands Commission on Genetic Modification (COGEM) commissions third-party research to support its work. The following project is open for enrollment: Germline modification and new gene therapies; an exploration. This project is a collaboration with the Central Committee on Research Involving Human Subjects (CCMO), and aims to gain insight into the likelihood of unintended germline modification in new (non-viral) gene therapies to support risk analysis. Interested parties are invited to submit a project bid. More information can be read here.
The National Institute for Public Health (RIVM) has, after close consultation with various parties including the NVGCT, written a report about the potential of DNA technology in improving public health(care). This will be used by the Ministry of Health, Welfare and Sport to develop a policy plan. More information and the report can be found here.
Company
MeiraGTx Netherlands is an Amsterdam based biopharmaceutical company developing local gene therapy for different indications. The company specializes in the development of viral gene therapy vectors, in particular adeno-associated virus (AAV) based therapeutics. Several product candidates are in the discovery and development phase. In our programs, we collaborate with world leading scientists.
Position
MeiraGTx Netherlands is seeking a motivated technician to join our team. He/she will be involved in the execution of current and new projects and external collaborations, focusing on the generation of new AAV-based vectors targeting inflammatory disease. The aim of these projects is to develop new product candidates for clinical testing. In addition, the research should generate new intellectual property to protect the company’s future products. The technician’s main responsibility is to perform quality control on vectors produced by MeiraGTx Netherlands, using molecular and biochemical techniques, and setting up of new analytical assays to characterize vector batches. Furthermore, the technician will be involved in production and purification of research batches of vectors. The technician will have a unique opportunity to participate in multidisciplinary collaborative research at MeiraGTx.
Education and experience requirements
MeiraGTx Netherlands offers the opportunity to work in an exciting and entrepreneurial environment. We allow you to grow within an organization that encourages talent, and that supports the development of its employees and fuels excellence. We are project focused and have built a culture with a high degree of personal empowerment. Our energetic and enthusiastic employees participate in and influence the long-term growth of MeiraGTx.
To apply, please send your full resume and motivation by e-mail to our Manager Operations Anouk Veneboer, e-mail: Anouk.Veneboer@meiragtx.com / Address: Paalbergweg 2-4, 1105 AG Amsterdam, The Netherlands. Phone: +31 682229139. For questions related to the position, please contact Mostafa Zahmatkesh (project lead vector productions and process development) Mostafa.Zahmatkesh@meiragtx.com).
